The combination of metformin and the EZH2 inhibitor GSK126 synergistically inhibits PCa cell growth in vitro and in vivo, affirming metformin as a promising therapeutic approach for future prostate cancer treatment (Chen et al., 2020). The gene discussed is EZH2; the disease is posterior cortical atrophy.